The FDA has signed emergency authorizations for unapproved uses of GlaxoSmithKline's Relenza, Roche Holding's Tamiflu and the rRT-PCR Swine Flu Panel diagnostic test in response to the public health emergency declared amid the swine flu outbreak. The swine flu strain reportedly has infected more than 40 people in the U.S.

Related Summaries